Timothy Walbert - Horizon Pharma Chairman, CEO and Pres

Chairman

Mr. Timothy P. Walbert is Chairman of the Board, President, Chief Executive Officer of the Company. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a public biopharmaceutical company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multiindication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. Mr. Walbert also serves as chairman of the board of directors of Egalet Corporationrationration, a public pharmaceutical company. Mr. Walbert sits on the board of directors of the Illinois Biotechnology Innovation Organization, the Biotechnology Innovation Organization, World Business Chicago and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council. Mr. Walbert previously served on the board of directors of Raptor Pharmaceutical Corporationration, a public biopharmaceutical company, from 2010 to 2014 XOMA Corporationrationration, a public biotechnology company, from 2010 to 2017 and Sucampo Pharmaceuticals, Inc., a public biopharmaceutical company, from March 2016 to February 2018 since 2010.
Age 56
Tenure 15 years
Phone353 1 772 2100
Webhttps://www.horizontherapeutics.com
Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania.

Timothy Walbert Latest Insider Activity

Tracking and analyzing the buying and selling activities of Timothy Walbert against Horizon Pharma stock is an integral part of due diligence when investing in Horizon Pharma. Timothy Walbert insider activity provides valuable insight into whether Horizon Pharma is net buyers or sellers over its current business cycle. Note, Horizon Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Horizon Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Horizon Pharma Management Efficiency

The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Horizon Pharma PLC currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Horizon Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

CHAIRMAN Age

Daniel VasellaNovartis AG ADR
65
Robert BradwayAmgen Inc
62
Jennifer TaubertJohnson Johnson
61
Alex GorskyJohnson Johnson
64
Robert JDMerck Company
58
Carlos AlbanAbbVie Inc
55
Paulus StoffelsJohnson Johnson
57
Joerg ReinhardtNovartis AG ADR
65
Robert MichaelAbbVie Inc
55
Daniel ODayGilead Sciences
60
Giovanni CaforioBristol Myers Squibb
56
Alex KrauerNovartis AG ADR
69
Richard GonzalezAbbVie Inc
71
Leif JohanssonAstraZeneca PLC ADR
68
Ashley McEvoyJohnson Johnson
50
Kenneth FrazierMerck Company
67
Enrico VanniNovartis AG ADR
70
Thibaut MongonJohnson Johnson
51
Joaquin DuatoJohnson Johnson
62
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois Chicago, Illinois Lake Forest, Illinois South San Francisco, California Washington, D.C. Gaithersburg, Maryland Rockville, Maryland and Mannheim, Germany. Horizon Therapeutics is traded on NASDAQ Exchange in the United States. Horizon Pharma PLC (HZNP) is traded on NASDAQ Exchange in USA and employs 2,190 people.

Management Performance

Horizon Pharma PLC Leadership Team

Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jane Gonnerman, Office Staff
Sean JD, Exec Counsel
Timothy Walbert, Chairman, CEO and Pres
Tina Ventura, Senior Vice President Investor Relations
Patrick McIlvenny, VP Officer
Paul Hoelscher, CFO and Executive VP of Fin.
FACP FACP, Ex Officer
Andy Pasternak, Ex Officer
Aaron Cox, Exec CFO
Geoffrey Curtis, Senior Vice President - Corporate Communications

Horizon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in Horizon Stock

If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
CEOs Directory
Screen CEOs from public companies around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk